AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01545414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ICONTROL
Description: 12 weeks of Internet-based treatment with a focus on relaxation training
Study NCT01596192 — intervention group
Intervention type: OTHER
Intervention: PETCT
Description: CT-PET will be performed within 3 days from acute GVHD diagnosis. Each patient will receive 400-610 MBq (11-16.5 mCi) of 18F-FDG intravenously. After tracer injection, the patients will rest on a comfortable chair during the 18F-FDG-uptake period, and drink with 150-300mg Levolac (Fresenius Kabi, Austria) diluted in 1000-1500cc water. CT-PET will be initiated 45-50 min after injection of the 18F-FDG.ll scans will be performed on a Discovery STE PET/CT scanner (General Electric Medical Systems, Milwaukee, WI).~CT will be performed 45-50 minutes after drinking the diluted lactulose solution had been ingested. The CT images will be acquired from the diaphragm to the symphysis pubis. After IV administration of 100 ml of nonionic contrast medium at a flow rate of 2.5 ml/sec.
Study NCT01807091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive outpatient induction chemotherapy
Study NCT02667015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy (Anxiety Sensitivity Intervention)
Description: 3 week, 6-session psychotherapy targeting anxiety sensitivity
Study NCT06442306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: Pain Neuroscience Education (PNE) is a cognitive-based education intervention that aims to change pain beliefs in patients experiencing CMP. Researchers have found PNE beneficial in assisting patients to reframe their understanding, attitudes, thoughts, and beliefs regarding their pain experience. PNE directs patients to relate chronic pain to overly sensitive nerves rather than assumed tissue damage. Further, PNE encourages patients to perform daily activities, work, and function in society, all despite pain. This facilitates behavior changes that are key in amending a patient's biopsychosocial state. Multiple sources make a strong case for the incorporation of PNE in having positive effects on reducing physical disability and modulating fear and anxiety in patients with CMP. Researchers have established a positive influence of PNE toward decreased kinesiophobia and have demonstrated a relation between increased self-efficacy and increased functional ability.
Study NCT06442306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Health Education
Description: General Health Education included: 20 Benefits of Walking 30 Minutes a Day; Why You Should Quit: Smoking Cessation; Heat vs. Cold: How to Use it For Pain Control; Sleep Hygiene.
Study NCT01051323 — intervention group
Intervention type: DRUG
Intervention: methoxy polyethylene glycol-ep [Mircera]
Description: As prescribed by physician
Study NCT02460367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02460367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tergenpumatucel-L
Study NCT02460367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Study NCT03219619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cap-EGD
Description: Undergoing cap-assisted endoscopy
Study NCT03916120 — intervention group
Intervention type: GENETIC
Intervention: Genetic analysis
Description: Collect 2ml intravenous blood from patients after anaesthesia.
Study NCT01386827 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mouse brain derived japanese encephalitis vaccine (MB-JEV)
Description: a) 2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 immunization and one booster dose of Ixiaro 0.5 ml > 2 years later
Study NCT01386827 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary and booster immunizations with MB-JEV
Description: 2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 as primary immunization and one booster dose of 0.5 ml > 2 years later
Study NCT01386827 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: C) primary immunizations with Ixiaro
Description: 2 0.5 ml doses of Ixiaro 28 days apart
Study NCT03219619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duo
Description: Undergoing side-viewing duodenoscope
Study NCT03987022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol
Description: Use of pain medication postoperatively
Study NCT03987022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Motrin
Description: Use of non-steroidal anti-inflammatory drug for pain control postoperatively
Study NCT03987022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilaudid Injectable Product
Description: Use of narcotic for pain control postoperatively
Study NCT01386827 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: S) Ixiaro booster to MBJEV primed
Description: 0.5ml Ixiaro to volunteers previously primed with 2-3 doses of MB-JEV
Study NCT03470441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDY-5301
Description: FDY-5301 will be administered once, intravenously, by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
Study NCT04645576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face correction with injectable fillers
Description: Injection of hyaluronic acid-based fillers
Study NCT03470441 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
Study NCT04482881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Mononitrate 40 MG
Description: giving women isosorbide mononitrate 40 MG
Study NCT04482881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Mononitrate 60 MG
Description: giving women isosorbide mononitrate 60MG
Study NCT04482881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Giving women misoprostol
Study NCT01564381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ResA
Description: 90mg of resveratrol conjugated with arginine.
Study NCT01564381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 90mg of resveratrol.
Study NCT01564381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Made up of cellulose.
Study NCT03005314 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: chemotherapy
Description: chemotherapy before surgery
Study NCT03005314 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: chemotherapy after surgery
Study NCT00819806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine only
Description: PF-3512676, Montanide ISA 720 VG and MHC class I peptides from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. The remaining 1.5 ml will be used for sterility testing. Each injection will be done in the vicinity of the nodal drainage of one extremity.
Study NCT00819806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine + cyclophosphamide
Description: PF-3512676, Montanide ISA 720 VG and three MHC class I-restricted epitopes from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) and cyclophosphamide. The vaccine preparation is identical to arm A. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
Study NCT00819806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine only
Description: PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102) and three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
Study NCT00819806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine + cyclophosphamide
Description: PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102), three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) and cyclophosphamide. The vaccine preparation is identical to arm C. Low-dose cyclophosphamide (300mg/m2) IV will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
Study NCT00819806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine only
Description: PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injection (i.e. 3 mg of PF-3512676 or 300 μl of PF-3512676 at 10mg/ml, 300 μg or 900 μl of protein NY-ESO-1 at 0.35 mg/ml + Montanide ISA 720 VG). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml SC injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
Study NCT00819806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine + cyclophosphamide
Description: PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injections and cyclophosphamide. The vaccine preparation is identical to arm E. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
Study NCT02052050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability
Study NCT04669847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk-oriented exercise program
Description: The trunk-oriented exercise program was performed by a physiotherapist two days of the week for 8 weeks.Trunk-oriented exercises were specially adapted to the patient based on the patient's functional status and active participation in the exercises.
Study NCT04669847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercise program
Description: Conventional exercise program was performed daily for 8 weeks, twice a day, on average 45 minutes, each exercise 5-10 repetitions. The program formed stretching exercises, and active or active-assisted strength exercises (upper extremity, lower extremity, abdominal muscles, back muscles).
Study NCT03987022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dilaudid Injectable Product
Description: Use of narcotic for pain control postoperatively
Study NCT03987022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet 5Mg-325Mg Tablet
Description: Use of combination tablet of Tylenol and Oxycodone for pain control postoperatively
Study NCT04013542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT04013542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04013542 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04645576 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Face correction with injectable fillers
Description: Injection of hyaluronic acid-based fillers
Study NCT01711580 — intervention group
Intervention type: OTHER
Intervention: EORTC QLQ-C30
Description: The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head \& Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
Study NCT01711580 — intervention group
Intervention type: OTHER
Intervention: EORTC QLQ-BN20
Description: The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head \& Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
Study NCT01711580 — intervention group
Intervention type: OTHER
Intervention: Hopkins Verbal Learning Test-Revised (HVLT-R)
Description: The HVLT-R is a cognitive test to assess verbal learning and memory.
Study NCT01711580 — intervention group
Intervention type: OTHER
Intervention: Stroop color-word test
Description: The Stroop Color and Word Test is a brief five minute test which is used to assess brain dysfunction, cognition, and psychopathology.
Study NCT01711580 — intervention group
Intervention type: OTHER
Intervention: Controlled oral word association test (COWA)
Description: The COWA is a measure of verbal fluency that requires expressive language and executive functions.
Study NCT01711580 — intervention group
Intervention type: OTHER
Intervention: Jamar hand dynamometer
Description: The Jamar hand dynamometer is a screening instrument that is used to assess grip strength.
Study NCT01711580 — intervention group
Intervention type: OTHER
Intervention: EORTC QLQ- FA13
Description: The Fatigue Questionnaire (QLQ-FA13) is a 13-item questionnaire to assess fatigue in patients with cancer. It is meant to be used in conjunction with the EORTC QLQ-C30
Study NCT01711580 — intervention group
Intervention type: OTHER
Intervention: Trail Making Test (TMT)
Description: The TMT The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy.
Study NCT04263493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation (physiotheraphy)
Description: Time of loading, range of motion exercises, strength training
Study NCT04263493 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation (physiotheraphy)
Description: Time of loading, range of motion exercises, strength training
Study NCT03538990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH Eating Pattern
Description: The DASH diet is a heart-healthy eating pattern that is focused on adequate consumption of fruits, vegetables, whole grains, low-fat dairy, fish, poultry, beans, nuts, and vegetables oils while emphasizing limited intake of foods containing saturated fat, such as fatty red meats, full-fat dairy products, and tropical oils, such as coconut, palm kernel, and palm oils, as well as sugar-sweetened beverages and sweets.
Study NCT00195624 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Campath )
Description: Campath administered at a dose of 10/mg/day for 10 days
Study NCT00195624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit. Dosing will be based on ideal body weight and will be adjusted to maintain a target level of 200 - 400 ng /ml.
Study NCT02685618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Study NCT02685618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02685618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phillips M1006B, offset by -10mmHg
Description: Administration of blood pressure module M1006B: offset by -10 mmHg
Study NCT02685618 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Phillips M1006B, offset by -10mmHg
Description: Administration of blood pressure module M1006B: offset by -10 mmHg
Study NCT02685618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips M1006B, No offset
Description: Administration of blood pressure module M1006B: No offset
Study NCT02685618 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Philips M1006B, No offset
Description: Administration of blood pressure module M1006B: No offset
Study NCT05882123 — intervention group
Intervention type: OTHER
Intervention: cerebral microbleeds
Description: Whether patients with acute ischemic stroke are complicated by cerebral microbleeds
Study NCT02044406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181
Description: single dose (low to high dose)
Study NCT02044406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181, R
Description: powder for oral solution
Study NCT02044406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181, T2
Description: tablet, fasted
Study NCT02044406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1181181
Description: Placebo to BI 1181181
Study NCT02044406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181, T1
Description: tablet, fed
Study NCT02390609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment A) [Reference]
Description: Participants will receive Ibrutinib 560 milligram (mg) (4\*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.
Study NCT02390609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment B)
Description: Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.
Study NCT02390609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment C)
Description: Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.
Study NCT01609738 — intervention group
Intervention type: DEVICE
Intervention: Left ventricular septum pacing lead
Description: A left ventricular septum pacing lead is permanently placed by introducing a custom lead with extended helix transvenously and, after positioning it against the RV septum, driving it through the inter-ventricular septum into the LV endocardial layer.
Study NCT02114489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate
Description: Unique perfusion of ibandronate 3 mg IV
Study NCT03558698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Good ventilation
Description: Good ventilation with a low concentration of CO2
Study NCT03558698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ventilation CO2
Description: CO2 High and Good ventilation
Study NCT03558698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Poor Ventilation
Description: Poor ventilation with high concentrations of CO2 and bio effluents
Study NCT02114489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01152411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow stem cells
Description: Bone marrow stem cells; Single dose; Interventional fluoroscopy-guided injection into the renal artery.
Study NCT02725268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous solution.
Study NCT02725268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapanisertib capsules.
Study NCT02725268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1117
Description: MLN1117 capsules.
Study NCT00735527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Intra-nasal 0.1 mg/kg (maximum 4 mg) once
Study NCT00735527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Intra-venous 0.1 mg/kg (maximum 4 mg) once
Study NCT02963766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC
Study NCT02963766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC
Study NCT04220567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Exercise and Patient-centred education
Description: An eight-week programme based on 24 sessions of exercise supervised by a physiotherapist. Exercise will be carried out three times a week. Once a week the exercise session is performed autonomously by patient at home (according to the physiotherapist's recommendations).~Patient-centred Education will follow the principles of transformative learning \& incorporate patients' narratives. It will precede 9 of the 24 exercise sessions and be delivered by the same physiotherapist
Study NCT04220567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Exercise
Description: An eight-week programme based on 24 sessions of exercise supervised by a physiotherapist. Exercise will be carried out three times a week. Once a week the exercise session is performed autonomously by patient at home (according to the physiotherapist's recommendations).